THE BUSINESS OF BIOTECH

43:46 24_01_BoB_1280x720_Ep245
BoB@JPM: Kasper Roet, Ph.D., QurAlis

On this episode of the Business of Biotech, Life Science Leader's Ben Comer joins to co-host a conversation with Dr. Roet that goes deep on his company's genetic medicine approach to ALS, and even deeper into his opinions on, and growing influence over, the regula...

ABOUT THE BUSINESS OF BIOTECH

Created exclusively for the leaders of new and emerging biopharma firms, The Business of Biotech tackles organizational, funding, HR, regulatory, production and CMC considerations with insight from peer founders who have taken biologic therapies from an idea to clinical success.

FEATURED GUESTS

Kasper Roet
QurAlis
PLAY
Rick Modi
Affinia Therapeutics
PLAY
Brad Sitko
XOMA Royalty
PLAY
Owen Hughes
XOMA Royalty
PLAY
Thomas Chalberg
Genascence
PLAY
Ran Zheng
Landmark Bio
PLAY
Peter Anastasiou
Capsida Biotherapeutics
PLAY
Stefan Scherer
3T Bioscience
PLAY
Jim Doherty
Acumen Pharmaceuticals
PLAY
Andrey Doronichev
BIOPTIC
PLAY
Jeff Coller
Johns Hopkins University RNA Innovation Center
PLAY
Michelle Kim
Johns Hopkins University RNA Innovation Center
PLAY
Apple Spotify   YouTube

MEET THE HOST

Matty PHosted by Bioprocess Online Chief Editor Matt Pillar, The Business of Biotech brings you weekly intelligence and insight, from leading voices in the biotech industry.

LINKEDIN SEND FEEDBACK

Interested in joining us on air? Contact us

bob-nl-tile-v2-350

RECENT EPISODES

43:46 24_01_BoB_1280x720_Ep245

BoB@JPM: Kasper Roet, Ph.D., QurAlis

52:20 24_01_BoB_1280x720_Ep244

BoB@JPM: Rick Modi, Affinia Therapeutics

56:27 24_01_BoB_1280x720_Ep243

BoB@JPM: Owen Hughes & Brad Sitko, XOMA Royalty

47:59 24_01_BoB_1280x720_Ep242

BoB@JPM: Tom Chalberg, Ph.D., Genascence

37:00 24_01_BoB_1280x720_Ep241

BoB@JPM: Ran Zheng, Landmark Bio

45:07 24_01_BoB_1280x720_Ep240

BoB@JPM: Peter Anastasiou, Capsida Biotherapeutics

43:00 24_01_BoB_1280x720_Ep239

BoB@JPM: Stefan Scherer, M.D., Ph.D., 3T Bioscience

47:50 24_01_BoB_1280x720_Ep238

The Business Of CNS with Acumen's Jim Doherty, Ph.D.

1:13:36 24_01_BoB_1280x720_Ep237

High-Throughput Discovery With BIOPTIC's Andrey Dobry

1:06:32 24_01_BoB_1280x720_Ep236

RNA Sandbox with Johns Hopkins RNA Innovation Center's Jeff Coller, Ph.D. and Michelle Kim, Ph.D.

More Recent Episodes

FINANCE & CAPITAL MARKETS

42:37 24_01_BoB_1280x720_Ep37

A CFO's Prescription For Biopharma Success

1:14:40 24_01_BoB_1280x720_Ep155

Origins Of A Biopharma VC Deal With Bernat Olle, Ph.D. And Parag Shah

45:24 24_01_BoB_1280x720_Ep77

The Year's Top Stories With Allan Shaw

55:03 24_01_BoB_1280x720_Ep184

Building A Biotech Hub With Intellia Therapeutics' John Leonard, M.D.

35:37 24_01_BoB_1280x720_Ep3

Episode 3: The Biopharma Exit Strategy With Dr. Francois Nader

59:45 24_01_BoB_1280x720_Ep147

Building Flagship Pioneering With Avak Kahvejian, Ph.D.

43:00 24_01_BoB_1280x720_Ep239

BoB@JPM: Stefan Scherer, M.D., Ph.D., 3T Bioscience

52:20 24_01_BoB_1280x720_Ep244

BoB@JPM: Rick Modi, Affinia Therapeutics

57:48 24_01_BoB_1280x720_Ep174

The Legend Steve Gorlin's Golden Rules

48:30 24_01_BoB_1280x720_Ep60

iNK T-Cell Immuno-oncology For Solid Tumors With Dr. Ian Walters

More on Finance & Capital Markets

DISCOVERY

38:25 24_01_BoB_1280x720_Ep34

Pioneering Antiviral Conjugates With Cidara's Dr. Jeff Stein

45:21 24_01_BoB_1280x720_Ep64

Building A DNA Delivery System With Poseida Tx CEO Eric Ostertag, M.D., Ph.D.

1:04:21 24_01_BoB_1280x720_Ep153

The Face Of African Biotech with Adrienne Leussa, Ph.D.

51:59 24_01_BoB_1280x720_Ep124

RNA-Based Therapeutics With Nutcracker Therapeutics' Dr. Geoff Nosrati

1:01:45 24_01_BoB_1280x720_Ep115

Epigenomic Programming With Omega Therapeutics' Mahesh Karande

52:40 24_01_BoB_1280x720_Ep112

Genetic Testing & Neurodegenerative Disorders With AviadoBio's Lisa Deschamps

28:13 24_01_BoB_1280x720_Ep178

mRNA Vaccine Platforms With Combined Therapeutics' Dr. Romain Micol

40:06 24_01_BoB_1280x720_Ep15

Dr. Gaurav Shah: Rocket's Chief Gene Therapist & Virtuoso

35:53 24_01_BoB_1280x720_Ep12

Arrowhead Pharma Pres. & CEO Dr. Christopher Anzalone On Taking RNA Interference Beyond The Liver

45:51 24_01_BoB_1280x720_Ep188

Reprogramming Human Cells With bit.bio's Mark Kotter, M.D.

More on Discovery

REGULATORY

31:52 24_01_BoB_1280x720_Ep130

Dissecting Spesolimab's Approval With Boehringer Ingelheim's Carine Boustany

55:25 24_01_BoB_1280x720_Ep233

Biotech Story Time With Tal Zaks, M.D. (Part 1)

41:26 BoB_Ep11

Taking ADCs Across The Finish Line

47:28 24_01_BoB_1280x720_Ep117

IND For TIL Therapy With Obsidian Therapeutics' Paul Wotton, Ph.D.

37:35 24_01_BoB_1280x720_Ep25

Manipulating Milestones In Pandemic Times With AGTC's Sue Washer

37:03 BoB_Ep67_2

The Clinical Trials Conundrum With Allan Shaw

38:19 24_01_BoB_1280x720_Ep19

Gap Analysis With Dr. Pablo Valenzuela & Cristián Hernández-Cuevas

47:50 24_01_BoB_1280x720_Ep238

The Business Of CNS with Acumen's Jim Doherty, Ph.D.

45:26 24_01_BoB_1280x720_Ep230

Novel Peptide Delivery With Revolo's Woody Bryan, Ph.D.

43:46 24_01_BoB_1280x720_Ep245

BoB@JPM: Kasper Roet, Ph.D., QurAlis

More on Regulatory

MANUFACTURING

52:48 24_01_BoB_1280x720_Ep164

Building LEO Pharma's U.S. Presence with Brian Hilberdink

42:18 24_01_BoB_1280x720_Ep29

Orchard Tx's Bobby Gaspar On Manufacturing Hematopoietic Stem Cells

53:35 24_01_BoB_1280x720_Ep163

Managing Momentum With Rezolute Bio's Nevan Charles Elam, JD

45:06 24_01_BoB_1280x720_Ep82

A Hybrid mAb Manufacturing Model With John Glasspool

35:29 BoB_Ep65_2

CDMO With A Pipeline Featuring Forge Biologics President & CEO Dr. Timothy J. Miller

56:17 24_01_BoB_1280x720_Ep99

Inflammation & Antibodies With Ampio Pharmaceutical's Mike Martino, CEO

48:02 24_01_BoB_1280x720_Ep51

A Scale-Up Story With Solis BioDyne Drs. Kadri Artma And Angela Vaasa

1:01:16 24_01_BoB_1280x720_Ep116

Regenerative Wound Care With BioStem Technologies' Jason Matuszewski & Andrew VanVurst

36:25 BoB_Ep66_2

CMC Developability Assessments For Rapid Ph.1 Entry With AltruBio's Gene Lee, Ph.D.

1:00:55 24_01_BoB_1280x720_Ep110

Observations On Outsourcing With Molecule To Market's Raman Sehgal

More on Manufacturing